Pieris Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/812,069 Titled "Muteins Of Human Lipocalin 2 With Affinity For A Given Target (For The Diagnosis And Treatment Of Tumor Diseases)"
Portfolio Pulse from Happy Mohamed
Pieris Pharmaceuticals has received a notice of allowance for its U.S. patent application 16/812,069 titled 'Muteins of Human Lipocalin 2 with Affinity for a Given Target (For the Diagnosis and Treatment of Tumor Diseases)'.
July 24, 2023 | 7:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pieris Pharmaceuticals has received a notice of allowance for its U.S. patent application, which could potentially lead to new products and revenue streams.
The notice of allowance for Pieris Pharmaceuticals' patent application indicates that the company is likely to receive the patent. This could potentially lead to the development of new products for the diagnosis and treatment of tumor diseases, which could in turn lead to new revenue streams for the company. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100